![](/wp-content/uploads/2023/11/Screenshot-2023-11-02-at-1.19.56-PM.png)
$599
SELECT Receives Priority Review; High-dose Oral Sema Delayed; Novo Q3 ’23 Earnings
Novo Nordisk hosted its Q3 ’23 earnings call (press release; slides) and provided updates across its CVRM portfolio. Novo provided important new disclosures including SELECT’s priority review, a high-dose oral sema regulatory filing delay, and a new subcutaneous amycretin asset in Ph1 development. Below, FENIX provides highlights and insights from the call, including thoughts on why SC amycretin makes sense from a strategic standpoint.